Department of Respiratory and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou Hospital Affiliated to Xuzhou Medical University, Xuzhou, China.
Department of Respiratory and Critical Care Medicine, The Xuzhou School of Clinical Medicine of Nanjing Medical University, Xuzhou, China.
Scand J Immunol. 2024 Sep;100(3):e13393. doi: 10.1111/sji.13393. Epub 2024 Jun 24.
It is urgent to explore factors affecting immunotherapy efficacy to benefit non-small cell lung cancer (NSCLC) patient survival. Bioinformatics predicted genes associated with programmed cell death ligand 1 (PD-L1) expression and analysed phospholipase A2 group IID (PLA2G2D) expression in NSCLC. BODIPY 493/503 dye staining and kits detected lipids, triglycerides, and phospholipids in H1299 cells, respectively. Extracellular vesicles (EVs) were extracted for morphology and size assessment using electron microscopy. Western blot assayed CD9, CD63, HSP90, EVs-PD-L1, PD-L1, and PLA2G2D expression. CCK-8, LDH, and ELISA tested proliferation and toxicity of CD8 T cells, interleukin-2, and interferon-gamma secretion, respectively. PLA2G2D, PD-L1, and Ki67 expression was detected by immunohistochemistry. Immunofluorescence assayed PLA2G2D localisation and CD8 T cell content. Flow cytometry assessed PD-L1 and CD8 expression. In NSCLC, upregulated EVs-PD-L1 and clinical characteristics showed a strong correlation. H1299 cells with overexpression PD-L1 significantly reduced proliferation, toxicity of CD8 T cells, and interleukin-2 and interferon-gamma levels. Bioinformatics revealed positive correlations between PLA2G2D and overexpressed PD-L1. PLA2G2D was expressed in macrophages and dendritic cells in NSCLC tissue. Overexpression PLA2G2D (oe-PLA2G2D) increased lipids, triglycerides, and phospholipids contents in H1299 cells. oe-PLA2G2D significantly reduced proliferation, toxicity of CD8 T cells, and interleukin-2 and interferon-gamma levels. si-PD-L1 restored inhibition of oe-PLA2G2D on CD8 T cells. oe-PLA2G2D significantly increased mice tumour volume and weight, upregulated expression of blood EVs-PD-L1 and tissue PD-L1, PLA2G2D, Ki67, and decreased CD8 T cell content. PLA2G2D facilitated immune escape in NSCLC by regulating CD8 T cell immune function by upregulating EVs-PD-L1.
迫切需要探索影响免疫治疗疗效的因素,以改善非小细胞肺癌(NSCLC)患者的生存。生物信息学预测了与程序性死亡配体 1(PD-L1)表达相关的基因,并分析了 NSCLC 中磷脂酶 A2 组 IID(PLA2G2D)的表达。BODIPY 493/503 染料染色和试剂盒分别检测 H1299 细胞中的脂质、甘油三酯和磷脂。提取细胞外囊泡(EVs),使用电子显微镜评估其形态和大小。Western blot 检测 CD9、CD63、HSP90、EVs-PD-L1、PD-L1 和 PLA2G2D 的表达。CCK-8、LDH 和 ELISA 分别检测 CD8 T 细胞的增殖和毒性、白细胞介素-2 和干扰素-γ的分泌。免疫组化检测 PLA2G2D、PD-L1 和 Ki67 的表达。免疫荧光检测 PLA2G2D 定位和 CD8 T 细胞含量。流式细胞术检测 PD-L1 和 CD8 的表达。在 NSCLC 中,上调的 EVs-PD-L1 与临床特征呈强相关。过表达 PD-L1 的 H1299 细胞显著降低了 CD8 T 细胞的增殖、毒性和白细胞介素-2 和干扰素-γ水平。生物信息学显示 PLA2G2D 与过表达的 PD-L1 呈正相关。PLA2G2D 在 NSCLC 组织中的巨噬细胞和树突状细胞中表达。过表达 PLA2G2D(oe-PLA2G2D)增加了 H1299 细胞中的脂质、甘油三酯和磷脂含量。oe-PLA2G2D 显著降低了 CD8 T 细胞的增殖、毒性和白细胞介素-2 和干扰素-γ水平。si-PD-L1 恢复了 oe-PLA2G2D 对 CD8 T 细胞的抑制作用。oe-PLA2G2D 显著增加了小鼠肿瘤体积和重量,上调了血液 EVs-PD-L1 和组织 PD-L1、PLA2G2D、Ki67 的表达,降低了 CD8 T 细胞含量。PLA2G2D 通过上调 EVs-PD-L1 调节 CD8 T 细胞免疫功能,促进 NSCLC 中的免疫逃逸。